Thomas Soldner

@BAMBossie81 @BiotechAutist The truth is, when more BP's would be interested, the company would be sold already. They have not much cash because investors are not really interested. The question is why? The clinical data of this product is very good, isn't it? $IMNN

@BiotechAutist thanks Sir Have a look at $IMNN 2 Things can happen there 1 Dilute to oblivion Partner/Sell Quick notes:

$IOVA dropped a second bomb NEXT to BANGER earnings Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas Not sure if I think this is strategically 'sound' , I prefer PR's to be spread

@bkfViking123 Especially when you are better than Astra Zeneca, who started their phase 3 trial with their CD19/BCMA targeting car-t weeks ago and bought Gracell for 1 Billion. The whole industry is investing in that technology. $TPST

$tpst potentially best-in-class signals for dual-targeting CAR-T starters .... bet a deal happens.

$tpst clean 100% CR with good safety in r/r MM for a CD19/BCMA dual-targeting CAR-T is strong interim data — especially in a tough patient population.

@ElMonoGran42994 @jfais20 Another examples are $TPST and $IMNN. Good results with phase 2 randomized trials but investors don't like them. $CADL with a succesfull phase 3 in prostate cancer and enough cash but also low stock price. Early stage car-t Biotechs have been bought out between 1-2 billion.

@jfais20 In this market you need a successful p3 first…and even that may not be enough. Tons of microcaps having the same market disconnect (take $oncy for example)

$IMMP- 1L NSCLC P3 trial reached 50% of enrollment target, small Aussie company that continues to get overlooked Futility analysis in Q1, then finish patient enrollment in Q3 Big idea = expanding PD-1 benefit to ALL expression levels (especially low to none) with no added tox

@JacobPlieth What do you think the Tempest–Factor deal was really done for? For a big player that would like to get back strategically at AstraZeneca? $TPST

The enlarged $TPST prioritising a CD19 x BCMA Car-T (TPST-2003), just as $AZN launches its phase 3 study of (ex $GRCL) AZD0120/GC012F: clinicaltrials.gov/study/NCT07391…

Is it a reverse merger? Is it a fund raising? I've tried to decipher the $TPST Factor deal, which is structured to avoid litigation vs $CLLS & $AZN. Via @ApexOnco -> oncologypipeline.com/apexonco/node/…

$TPST Didn't think he would really merge with factor. Just thought he would use it as an option to negotiate with Big Pharma. Maybe the BO price was too low for the board. I don't know.

@BAMBossie81 I was misleading on the offering topic about Imunon. ChatGPT was confusing me. The offering must be executed, you don't need an extra 8-k filing that described the closing. Is that right? Sometimes ChatGPT describes it completely different .

@ThomasSold47382 Ah ok. I sold $LSTA - did not sit around and wait. Doubled up, moved on.

$IMNN is a bit of a binary bet. The lack cash. They must raise. They raised very little though. Thus remains a low float. Ovarian Cancer, like ADC $STRO $LSTA , is a hot space. The 1 thing that stands out is the CFO coming out of retirement/consultancy

@ShortSeller Let's look if the offering will be executed. If not, you know what's going on.

$SGMO So if you factor in the warrant using black Scholes the offering price was like .27 lol

@BAMBossie81 $LSTA has a different leverage strategy. They are using Kuvas offer as a floor for further negotiations. So till or after 27 February we should hear about a higher offer. $IMNN I also wonder about this low institutional holders %. Maybe they are buying before the offer PR.

@ThomasSold47382 I think that is very likely, or a meaningful partnership. I think this is data contingent Like $LSTA - this is under the radar

I hope $lsta is just setting the floor with this anouncement. This aquisition price is too low. The deadline of 27 February makes pressure for other interested buyers. I also hope $tpst is doing a better deal than the merger with Factor. February would be good, I'm impatient.

@ShortSeller Congratulations. I always try to find undervalued biotechs which will be succesfull in the future.

$TERN There is NOBODY who gives you potential 10X stocks again and again and again... #AnnualizeThis

@A_May_MD By the way, the CMO said in the conference that the PD-L1 negative population is prespecified. That's very important for approval.

What I find interesting about the $IOBT situation is the clear “hit” in the “true” PD1 naive population (mPFS 24.8 months vs 11.0). Maybe that seems like p-hacking to some, but that’s actually the main population here (n=371 of the n=407 trial). It’s especially interesting because the non-naive patients were those who got PD1 as adjuvant/neoadjuvant treatment (this is *supposed* to be a first line study after all). Adjuvant treatment of low stage melanomas didn’t even really start until ~2022 following KEYNOTE-716 results. So this “post-adjuvant” population that apparently derailed $IOBT’s trial here is a *new* type of patient population that prior studies would not have encountered. Older studies of pd1 combo like RELATIVITY for Nivo+Relatlimab likely had few to no patients who had done prior adjuvant PD1. In the “true first line” (i.e. no adjuvant PD1), population $IOBT hit on mPFS pretty resoundingly…even just a few years ago this would’ve be the only population that existed in a “first line” study. Seems like oversight to have allowed these adjuvant experienced patients in the trial…are PD1 adjuvant failed patients really “first line” patients still? Would the FDA allow $IOBT to submit the n=371 dataset of “true” first line patients for approval? I know it’s red right now, but seems plausible to me that $IOBT *could* end up green today.

@maddstone1 @GermanBiotech @jfais20 If you look at the share price of most biotechs then nothing has aroused interest. But that's not the point. What is important is, what is important for big pharma. And these molecules did a good job. The data of afm13 and Nk cells in Hodgin Lymphoma is impressive.

@ThomasSold47382 @GermanBiotech @jfais20 13 and 28 did Not draw interest anyway

$AFMD - bitter ending (another case of promising data, poor mgmt)

@radioonc @maddstone1 @GermanBiotech @jfais20 Of course they could have done it earlier and I think they had some offers. Think about the Roche deal some years ago. But what price do you get for a not much proven phase 1 asset? Not much. What do you get for a much more proven phase 2 asset with good data? Much more.

@ThomasSold47382 @maddstone1 @GermanBiotech @jfais20 Hopefully you're right, but if it is, why hasn't anyone interfered and done a hostile takeover, he can do it now with less than 2 million!!!!!!

@8thKingofRome @jfais20 It's okay. I understand you. It is looking very bad at the moment. We will see.

@ThomasSold47382 @jfais20 Thomas, this board has had pumpers like you calling BO since 10$ (current $100). I, my self, thought genuinely this was a candidate years ago. This is now trading at 0,01$ pre reverse split. Enough of this bullshits, thanks.

$AFMD when thesis weakens, important to take the loss & move on (feel for my friends who held til the bitter end) Good question to ask is what other names are we stubbornly bagholding when we should be cutting them loose?

@8thKingofRome @jfais20 The have a German Interims CFO with Harry Welten, I don't think so. By the way, a German Insolvency doesn't mean a shutdown next week. They have enough time to come to a buy-out.

@ThomasSold47382 @jfais20 More probable no advisors alerted them about german insolvency rules so they got caught

@maddstone1 @GermanBiotech @jfais20 Why just 50 million? The data of especially afm13 and afm28 is looking great. Call me crazy, but for me that company with that good platform was always worth about 5 billion. So when Affimed goes bankrupt, I don't know what to trust in Biotech anymore.

@ThomasSold47382 @GermanBiotech @jfais20 it might be delusional, but they say the talks ongoing...maybe someone is willing to pay 50 mio. then after paying back debt, the shareholders would get the rest

@GermanBiotech @jfais20 I did a little research and realised that $AFMD still owed 11 million. They must have paid it off early to clean up the balance sheet. If you ask me, that looks like a takeover of the company in June.

@ThomasSold47382 @jfais20 It is indeed difficult to understand.

@jfais20 They are cleaning up their balance sheet and you know why Jonathan.

@jfais20 I realised that $AFMD still has a loan of over $9 mil from SVB and has long-term debt of $2 mil, which it has probably paid off early. That's why they had to file for bankruptcy in Germany. The question now is, why do they pay their debts early and get themselves into trouble?

@jfais20 Strange situation. But the data of all 3 drugs are good. Especially AFM13 with NK-Cells. I would be surprised if there were no take-overs here.